4 articles featuring Pinene
Chemotherapy-induced nausea and vomiting (CINV) remains a primary driver of treatment non-compliance and reduced quality of life. Modern clinical standards are shifting. While traditional anti-emetics serve as the baseline, the $21 billion global supportive care market is increasingly incorporating cannabinoid therapeutics to fill efficacy gaps. Cannabis is now viewed as a strategic component of evidence-based supportive oncology.
The therapeutic application of cannabinoids for chemotherapy-induced nausea and vomiting (CINV) has evolved into a data-driven segment of oncology supportive care. As pharmaceutical-grade interventions become more common, THC-based formulations are being utilized for refractory cases where traditional anti-emetics may fall short.
'The munchies'—or clinically, hyperphagia—is a physiological response triggered when exogenous cannabinoids interact with your body’s endocannabinoid system (ECS). By binding to CB1 receptors in the hypothalamus and the olfactory bulb, specific cannabis compounds may influence how your brain perceives hunger, sensory pleasure, and metabolic homeostasis.
For the aging patient, chemotherapy-induced nausea and vomiting (CINV) represents a physiological challenge that tests a body already dealing with diminished internal resources. As patients age, natural endocannabinoid tone—the body’s innate signaling system—often declines, which may leave seniors with fewer defenses against the systemic stress of oncology treatments. Integrating phytocannabinoids may support the restoration of biological equilibrium that chemotherapy often disrupts.